<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619837</url>
  </required_header>
  <id_info>
    <org_study_id>18-24323</org_study_id>
    <nct_id>NCT03619837</nct_id>
  </id_info>
  <brief_title>Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant</brief_title>
  <acronym>PRO-ACT:</acronym>
  <official_title>PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with
      livers or kidneys from donors who do have HCV. Medications that are used to treat HCV will be
      given to the study subjects shortly after transplant to protect them from developing the
      problems HCV can cause to the liver.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">September 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 11, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with HCV RNA level below limits of quantification (LOQ)</measure>
    <time_frame>12 weeks after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by the proportion of participants who prematurely discontinue antiviral therapy before the planned end of treatment</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Survival rate of patients and their allografts 6 months post liver transplant</measure>
    <time_frame>6 months from time of liver transplant</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Transplantation Disease Transmission</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm: Sofosbuvir/Velpatasvir
Dosage: 400mg/100mg. Once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/Velpatasvir</intervention_name>
    <description>Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/Velpatasvir/Voxilaprevir</intervention_name>
    <description>Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.
Dosage: 400mg/100mg/100mg daily for 12 weeks.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (â‰¥ 18 year-old), wait-listed for primary kidney or liver transplant without a
             potential suitable living donor or for simultaneous liver kidney transplant;

          -  HCV non-infected at the time of transplant. Subjects who were previously HCV infected
             but who have had documented SVR12 are eligible to participate;

          -  Agree to use two methods of birth control during the study;

          -  Donor characteristics: serum HCV NAT-positive and negative for hepatitis B surface
             antigen. For liver transplant: pre-donation liver biopsy with no fibrosis (F0) or
             minimal fibrosis (F1). For kidney transplant: kidney donor profile index &lt; 85%.

        Exclusion Criteria:

          -  Donor and/or recipient HIV infection

          -  Subject pregnant or nursing

          -  Donor and/or recipient Hepatitis B surface antigen positive

          -  Kidney-pancreas transplant

          -  Single organ liver recipients who received hemodialysis for more than 7 days prior to
             liver transplantation

          -  Kidney recipients: on dialysis for &gt; 5 years at time of Screening; subjects sensitized
             with panel reactive antibody &gt; 80%; for single organ kidney transplant, subjects with
             advanced liver fibrosis (Knodell stage 3) or cirrhosis

          -  Individuals being treated with and needing to continue rifabutin, rifampin,
             carbamazepine, phenytoin, phenobarbital, oxcarbazepine, St. John's wort (Hypericum
             perforatum), medium- or high-dose rosuvastatin or atorvastatin, or high-dose proton
             pump inhibitors (See Concomitant Medications).

          -  Individuals treated with amiodarone within 42 days of organ transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Niemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Research Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

